1 / 33

Key Research From IDSA 2007: The 45th Annual Meeting of the Infectious Diseases Society of America

Faculty Eric Daar, M.D. Key Research From IDSA 2007: The 45th Annual Meeting of the Infectious Diseases Society of America. San Diego, California | October 4-7, 2007. This activity is supported by an educational grant from. IDSA 2007: Faculty for This Activity. Eric Daar, M.D.

haamid
Télécharger la présentation

Key Research From IDSA 2007: The 45th Annual Meeting of the Infectious Diseases Society of America

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Faculty Eric Daar, M.D. Key Research From IDSA 2007:The 45th Annual Meeting of the Infectious Diseases Society of America San Diego, California | October 4-7, 2007 This activity is supported by an educational grant from

  2. IDSA 2007: Faculty for This Activity Eric Daar, M.D. Dr. Daar is the chief of HIV medicine at Harbor-UCLA Medical Center in Los Angeles, Calif., and a professor of medicine at the University of California-Los Angeles' David Geffen School of Medicine. He has been an active HIV physician and researcher since the 1980s; during the past three decades, he has led dozens of studies on a vast range of HIV-related issues, with a particular focus on coinfections and other health complications associated with HIV and HIV treatment, including hepatitis C, metabolic complications, cardiovascular disease and psychosocial issues such as depression.

  3. IDSA 2007: Key Research About This Presentation • This presentation was created to accompany The Body PRO's podcast summary of key research presented at IDSA 2007, featuring an interview with Eric Daar, M.D. For more information about this program, please visit us on the Web at: TheBodyPRO.com/IDSA2007 • Please feel free to use this slide presentation for personal reference or for your own presentations; however, we ask that you not modify any aspects of the slides contained within this presentation so proper attribution can be retained. If you would like to publish all or part of this presentation, or repost any of these slides online, you must first obtain permission from Body Health Resources Corporation. • Our gratitude goes out to all who granted permission for their slides to be adapted for this presentation. Disclaimer Knowledge about HIV changes rapidly. Note the date of this presentation's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this presentation.

  4. New Antiretroviral Options: Emerging Data From Recently Approved Agents or Agents Available in Expanded Access

  5. TITAN: Study Design W. David Hardy et al. IDSA 2007; abstract 1209. Reprinted with permission.

  6. TITAN: Virologic Response Through Week 48 (ITT-TLOVR) – All Patients W. David Hardy et al. IDSA 2007; abstract 1209. Reprinted with permission.

  7. TITAN: Difference in Virologic Response (VL <50 Copies/mL) at Week 48: Univariate Analysis W. David Hardy et al. IDSA 2007; abstract 1209. Reprinted with permission.

  8. TITAN: Baseline Characteristics W. David Hardy et al. IDSA 2007; abstract 1209. Reprinted with permission.

  9. TITAN: NRTIs and NNRTIs Used in the Optimized Background Regimen W. David Hardy et al. IDSA 2007; abstract 1209. Reprinted with permission.

  10. TITAN: Impact of IAS-USA Primary PI Mutations* at Baseline on VL <50 Copies/mL at Week 48 W. David Hardy et al. IDSA 2007; abstract 1209. Reprinted with permission.

  11. TITAN: Difference in Virologic Response (VL <50 Copies/mL, ITT-TLOVR): Multivariate Analyses W. David Hardy et al. IDSA 2007; abstract 1209. Reprinted with permission.

  12. Summary of Virologic Responses Without (-) and With (+) Enfuvirtide (ENF) Adapted from Jacob P. Lalezari et al. IDSA 2007; abstract 964.

  13. DUET 24-Week Efficacy: Patients With Viral Load <50 Copies/mL at Week 24 (Primary Endpoint; ITT-TLOVR) Charles Hicks et al. IDSA 2007; abstract 1207. Reprinted with permission.

  14. DUET 24-Week Efficacy: Mean Viral Load Reduction From Baseline (ITT NC=F) Charles Hicks et al. IDSA 2007; abstract 1207. Reprinted with permission.

  15. DUET 24-Week Efficacy: CD4 Cell Count Increase to 50 Cells/mm3 or Above Charles Hicks et al. IDSA 2007; abstract 1207. Reprinted with permission.

  16. DUET 24-Week Efficacy: Response (<50 Copies/mL) According to Number of Active Background Antiretrovirals Charles Hicks et al. IDSA 2007; abstract 1207. Reprinted with permission.

  17. DUET 24-Week Efficacy: Response (<50 Copies/mL) According to Baseline Viral Load and CD4 Cell Count Charles Hicks et al. IDSA 2007; abstract 1207. Reprinted with permission.

  18. DUET 24-Week Efficacy: Mutations Associated With a Decreased Response to TMC125 Charles Hicks et al. IDSA 2007; abstract 1207. Reprinted with permission.

  19. DUET 24-Week Efficacy: Response (<50 Copies/mL) According to Number of TMC125 RAMS Charles Hicks et al. IDSA 2007; abstract 1207. Reprinted with permission.

  20. DUET 24-Week Safety: Overview of Adverse Events AEs leading to death were not reported in more than one patient except for pneumonia and sepsis (n=2 each) in the placebo group None of the deaths in the TMC125 group were considered related to TMC125 *excluding injection site reactions; §p=0.0001 vs placebo; AE = adverse event Richard Haubrich et al. IDSA 2007; abstract 1210. Reprinted with permission.

  21. DUET 24-Week Safety: Grade 3 and 4 Adverse Events *excluding injection site reactions and grade 3/4 laboratory abnormalities reported as AEs Richard Haubrich et al. IDSA 2007; abstract 1210. Reprinted with permission.

  22. DUET 24-Week Safety: Rash In the TMC125 group: Early onset: Median 12 days. Limited duration: Median 11 days. Low severity: Most mild to moderate; 1.3% grade 3, none grade 4. Mostly maculopapular; no mucosal involvement. Infrequently led to discontinuation: 2.2% of patients (0% with placebo). Most resolved with continued treatment. Clinical associations with rash No association withbaseline CD4 cell count. No increased risk with prior NNRTI-related rash. Richard Haubrich et al. IDSA 2007; abstract 1210. Reprinted with permission.

  23. DUET 24-Week Safety: Psychiatric Disorders • Similar incidence to placebo: 13% in TMC125 group versus 15% in placebo group (p=0.3). • Low severity: mostly grade 1 and 2. • Infrequently lead to discontinuation: 1 patient (0.2%) in each group. • No increased risk in patients with a history of psychiatric disorders. • Abnormal dreams/nightmares in 5 patients (0.8%) in each group and no episodes of hallucinations, suicidal ideation or manic symptoms with TMC125. Richard Haubrich et al. IDSA 2007; abstract 1210. Reprinted with permission.

  24. DUET 24-Week Safety: Lipid Changes Over Time TMC125 group Placebo group High Density Lipoprotein Low Density Lipoprotein Calculated Change from baseline (mg/dL) Triglycerides Total Cholesterol/High Density Lipoprotein Change from baseline (mg/dL) Week Week Richard Haubrich et al. IDSA 2007; abstract 1210. Reprinted with permission.

  25. Placebo group DUET 24-Week Safety: Hospitalizations TMC125 group 1700 16% p=0.0031 1105 11% Patients hospitalized at least once by 24 weeks (%) Cumulative days hospitalized by 24 weeks Richard Haubrich et al. IDSA 2007; abstract 1210. Reprinted with permission.

  26. A4001029: Phase 2b Pilot Study Evaluating the Safety of Maraviroc in Patients With Non-R5 HIV-1 J.M. Goodrich et al. IDSA 2007; abstract LB-2. Reprinted with permission.

  27. A4001029: Baseline Characteristics J.M. Goodrich et al. IDSA 2007; abstract LB-2. Reprinted with permission.

  28. A4001029: Baseline Characteristics – Primary Study Population J.M. Goodrich et al. IDSA 2007; abstract LB-2. Reprinted with permission.

  29. A4001029: Percentage of Patients With Undetectable HIV-1 RNA Over 48 Weeks J.M. Goodrich et al. IDSA 2007; abstract LB-2. Reprinted with permission.

  30. A4001029: Mean Change From Baseline in CD4+ Count J.M. Goodrich et al. IDSA 2007; abstract LB-2. Reprinted with permission.

  31. A4001029: Summary of Week 48 Safety Results J.M. Goodrich et al. IDSA 2007; abstract LB-2. Reprinted with permission.

  32. A4001029: Number of Category C Events J.M. Goodrich et al. IDSA 2007; abstract LB-2. Reprinted with permission.

  33. IDSA 2007: Key Research • Visit The Body PRO for comprehensive coverage of IDSA 2007.This presentation was created to accompany The Body PRO's summary of key research presented at IDSA 2007, by Eric Daar, M.D. Learn more at: TheBodyPRO.com/IDSA2007 • In addition, be sure to browse through The Body PRO’s extensive coverage of IDSA 2007, which includes: • A full written summary with expert discussion and analyses of key research. • Downloadable MP3s: listen on your computer or download to your MP3 player. • Slides and in-depth data analyses. • Visit TheBodyPRO.com/IDSA2007 today for a full listing of our conference materials!

More Related